Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Mephenytoin, poor metabolism of

MedGen UID:: 322802
•Concept ID:: C1836024
•: Finding

Synonym:	MEPHENYTOIN, POOR METABOLISM OF

OMIM®:	124020; 609535

Professional guidelines

PubMed

The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Klotz U
Clin Pharmacokinet 2007;46(4):271-9. doi: 10.2165/00003088-200746040-00001. PMID: 17375979

CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.

Zhou HH
Clin Chim Acta 2001 Nov;313(1-2):203-8. doi: 10.1016/s0009-8981(01)00696-9. PMID: 11694260

Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease.

Tanaka E
J Clin Pharm Ther 1998 Jun;23(3):161-70. doi: 10.1046/j.1365-2710.1998.00135.x. PMID: 9831966

See all (25)

Recent clinical studies

Etiology

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Goldstein JA
Br J Clin Pharmacol 2001 Oct;52(4):349-55. doi: 10.1046/j.0306-5251.2001.01499.x. PMID: 11678778 Free PMC Article

Populations and genetic polymorphisms.

Weber WW
Mol Diagn 1999 Dec;4(4):299-307. doi: 10.154/MODI00400299. PMID: 10671640

Differences in interactions of SSRIs.

Brøsen K
Int Clin Psychopharmacol 1998 Sep;13 Suppl 5:S45-7. doi: 10.1097/00004850-199809005-00009. PMID: 9817620

Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.

Böttiger Y, Dostert P, Benedetti MS, Bani M, Fiorentini F, Casati M, Poggesti I, Alm C, Alvan G, Bertilsson L
Br J Clin Pharmacol 1996 Dec;42(6):707-11. doi: 10.1046/j.1365-2125.1996.00471.x. PMID: 8971425 Free PMC Article

Polymorphic drug metabolism.

Relling MV
Clin Pharm 1989 Dec;8(12):852-63. PMID: 2689060

See all (84)

Diagnosis

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.

Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K
Aliment Pharmacol Ther 2003 Jan;17(2):259-64. doi: 10.1046/j.1365-2036.2003.01406.x. PMID: 12534411

Populations and genetic polymorphisms.

Weber WW
Mol Diagn 1999 Dec;4(4):299-307. doi: 10.154/MODI00400299. PMID: 10671640

Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.

Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH
Pharmacogenetics 1997 Apr;7(2):115-9. doi: 10.1097/00008571-199704000-00004. PMID: 9170148

Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.

Madsen H, Hansen TS, Brøsen K
Pharmacogenetics 1996 Dec;6(6):513-9. doi: 10.1097/00008571-199612000-00004. PMID: 9014200

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.

Skjelbo E, Mutabingwa TK, Bygbjerg Ib, Nielsen KK, Gram LF, Brøosen K
Clin Pharmacol Ther 1996 Mar;59(3):304-11. doi: 10.1016/S0009-9236(96)80008-7. PMID: 8653993

See all (15)

Therapy

The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Klotz U
Clin Pharmacokinet 2007;46(4):271-9. doi: 10.2165/00003088-200746040-00001. PMID: 17375979

Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.

Vaswani M, Linda FK, Ramesh S
Prog Neuropsychopharmacol Biol Psychiatry 2003 Feb;27(1):85-102. doi: 10.1016/s0278-5846(02)00338-x. PMID: 12551730

CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.

Laine K, Anttila M, Nyman L, Wahlberg A, Bertilsson L
Eur J Clin Pharmacol 2001 May;57(2):137-42. doi: 10.1007/s002280100289. PMID: 11417445

Differences in interactions of SSRIs.

Brøsen K
Int Clin Psychopharmacol 1998 Sep;13 Suppl 5:S45-7. doi: 10.1097/00004850-199809005-00009. PMID: 9817620

Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.

See all (78)

Prognosis

Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells.

Deguchi S, Yamashita T, Igai K, Harada K, Toba Y, Hirata K, Takayama K, Mizuguchi H
Drug Metab Dispos 2019 Jun;47(6):632-638. Epub 2019 Apr 8 doi: 10.1124/dmd.119.086322. PMID: 30962288

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA
Pharmacogenetics 2002 Dec;12(9):703-11. doi: 10.1097/00008571-200212000-00004. PMID: 12464799

Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Desta Z, Zhao X, Shin JG, Flockhart DA
Clin Pharmacokinet 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. PMID: 12222994

Molecular mechanisms of genetic polymorphisms of drug metabolism.

Meyer UA, Zanger UM
Annu Rev Pharmacol Toxicol 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269. PMID: 9131254

Genetic polymorphisms of drug metabolism.

Meyer UA
Fundam Clin Pharmacol 1990;4(6):595-615. doi: 10.1111/j.1472-8206.1990.tb00041.x. PMID: 1982880

See all (32)

Clinical prediction guides

Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells.

Deguchi S, Yamashita T, Igai K, Harada K, Toba Y, Hirata K, Takayama K, Mizuguchi H
Drug Metab Dispos 2019 Jun;47(6):632-638. Epub 2019 Apr 8 doi: 10.1124/dmd.119.086322. PMID: 30962288

Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Desta Z, Zhao X, Shin JG, Flockhart DA
Clin Pharmacokinet 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. PMID: 12222994

Molecular mechanisms of genetic polymorphisms of drug metabolism.

Meyer UA, Zanger UM
Annu Rev Pharmacol Toxicol 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269. PMID: 9131254

Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.

Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-2 (IIC9).

Kato R, Yamazoe Y, Yasumori T
Xenobiotica 1992 Sep-Oct;22(9-10):1083-92. doi: 10.3109/00498259209051862. PMID: 1441599

See all (81)